Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration

Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg¹, Lennart Jacobsson², Michael J. Nissen³, Eirik K Kristianslund⁴, Maria José Santos⁵, Kari Eklund⁶, Ziga Rotar⁷, Björn Gudbjornsson⁸, Fatos Onen⁹, Catalin Codreanu¹⁰, Ulf Lindström¹¹, Cem Gabay³, Tore Kvien⁴, Anabela Barcelos⁵, Kalle Aaltonen⁶, Matija Tomšič⁷, Thorvardur Love⁸, Gerçek Can⁹, Ruxandra Ionescu¹⁰, Anne Gitte Loft¹, Herman F Mann¹², Karel Pavelka¹², Marleen van de Sande¹³, Irene van der Horst-Bruinsma¹⁴, Juan J. Gomez-Reino¹⁵, Carlos Sánchez-Piedra¹⁶, Gary J Macfarlane¹⁷, Florenzo Iannone¹⁸, Lise Hyldstrup¹, Niels Steen Krogh¹⁹, Mikkel Østergaard¹ and Merete Lund Hetland¹, ¹DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, ²ARTIS, EuroSpA Research Collaboration Network, Gothenburg, Sweden, ³SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, ⁴NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁵Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, ⁶ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, ⁷biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, ⁸ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, ⁹TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, ¹⁰RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, ¹¹ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, ¹²ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, ¹³ARC, EuroSpA Research Collaboration Network, Amsterdam, Netherlands, ¹⁴ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, ¹⁵BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁶BIOBASADER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁷BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, ¹⁸GISEA, EuroSpA Research Collaboration Network, Bari, Italy, ¹⁹ZiteLab ApS, Copenhagen, Denmark

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologics, Epidemiologic methods, outcomes, psoriatic arthritis and registries

Session Information

Date: Tuesday, October 23, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Drug retention and response rates of TNFi treatment in 13,170 patients with psoriatic arthritis treated in routine care – pooled data from the EuroSpA Research Network Collaboration

Background/Purpose:
A research network collaboration of 15 European registries sharing data on patients with spondyloarthritis (SpA), “EuroSpA”, has recently been created to strengthen research capabilities in the real world setting¹.
We aimed to investigate Tumour Necrosis Factor inhibitor (TNFi) retention and response rates at 6, 12 and 24 months in patients with psoriatic arthritis (PsA) treated with their 1^st, 2^nd or 3^rd TNFi in clinical practice across Europe.

Methods:
A common data model was agreed upon by the EuroSpA Scientific Committee. Registry data managers clarified data availability and uploaded anonymized data through the secure Virtual Private Network pipelines to the EuroSpA server. Baseline characteristics, drug retention and response rates were investigated with non-parametric descriptive statistics. Kaplan-Meier estimation was used to investigate TNFi retention rates. Both crude and Lundex adjusted² response rates were calculated for DAS28 remission (DAS28≤2.6) after 6, 12 and 24 months and ACR20/50/70 after 6 months.

Results:
In May 2018, 10 of the 15 registries participating in EuroSpA had completed data upload to the EuroSpA server, including 13,170 patients with PsA. Baseline characteristics of the pooled population are shown in Table.

For the 1^st TNFi, 6 and 24 months´ retention rates were 86% and 67%, respectively. Corresponding retention rates for the 2^nd TNFi were 79% and 59%, and for the 3^rd TNFi 77% and 55%, respectively (Table and Figure). For the 1^st TNFi, 6 and 24 months Lundex adjusted DAS28 remission rates were 44% and 30%. Corresponding remission rates for the 2^nd TNFi were 34% and 22%, and for the 3^rd TNFi, 26% and 16%. For the 1^st TNFi, 6 months Lundex adjusted ACR 20/50/70 response rates were 40%, 27% and 15%, respectively. Corresponding ACR 20/50/70 response rates for the 2^nd TNFi were 21%, 13% and 6% and for the 3^rd TNFi, 20%, 10% and 5%, respectively.

Conclusion:
These initial analyses demonstrate that the creation of a large European database of PsA patients treated in routine care based on a common data model is feasible, offering important opportunities for future research. In this pooled dataset from 10 European registries, we found decreasing retention rates and response rates with increasing number of previous TNFi.

References: 1)Ann Rheum Dis, 2017, suppl. 2, p.65
References: 2)Arthritis Rheum, 2006, 54(2), p.600-6.

Disclosure: C. H. Brahe, Novartis Pharmaceuticals AG, 2; L. M. Ørnbjerg, None; L. Jacobsson, None; M. J. Nissen, None; E. K. Kristianslund, None; M. J. Santos, Company A; Company B, 1, 8; K. Eklund, None; Z. Rotar, None; B. Gudbjornsson, None; F. Onen, None; C. Codreanu, None; U. Lindström, None; C. Gabay, AB2 Bio, Pfizer and Roche, 2,AB2 Bio, AbbVie, Bristol Myers Squibb, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, UCB, 5, 8; T. Kvien, None; A. Barcelos, None; K. Aaltonen, None; M. Tomšič, None; T. Love, None; G. Can, None; R. Ionescu, None; A. G. Loft, None; H. F. Mann, None; K. Pavelka, None; M. van de Sande, Dutch arthritis association, Janssen, Novartis, Eli Lily, 2,Abbvie, Novartis, 5; I. van der Horst-Bruinsma, AbbVie Inc., 2, 5,Pfizer, Inc., 2, 5,MSD, 2, 5,UCB, Inc., 2, 5; J. J. Gomez-Reino, None; C. Sánchez-Piedra, None; G. J. Macfarlane, None; F. Iannone, None; L. Hyldstrup, None; N. S. Krogh, None; M. Østergaard, None; M. L. Hetland, None.

To cite this abstract in AMA style:

Brahe CH, Ørnbjerg LM, Jacobsson L, Nissen MJ, Kristianslund EK, Santos MJ, Eklund K, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Lindström U, Gabay C, Kvien T, Barcelos A, Aaltonen K, Tomšič M, Love T, Can G, Ionescu R, Loft AG, Mann HF, Pavelka K, van de Sande M, van der Horst-Bruinsma I, Gomez-Reino JJ, Sánchez-Piedra C, Macfarlane GJ, Iannone F, Hyldstrup L, Krogh NS, Østergaard M, Hetland ML. Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/drug-retention-and-response-rates-of-tnfi-treatment-in-13170-patients-with-psoriatic-arthritis-treated-in-routine-care-pooled-data-from-the-eurospa-research-network-collaboration/. Accessed .

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/drug-retention-and-response-rates-of-tnfi-treatment-in-13170-patients-with-psoriatic-arthritis-treated-in-routine-care-pooled-data-from-the-eurospa-research-network-collaboration/